An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the one that causes COVID-19. The antibody, called S309, is now on a fast-track development and testing path at Vir Biotechnology in the next step toward possible clinical trials.
- Custom diets are essential to mental health, new research shows
- Do marketers matter for entrepreneurs?
- A new effect of red ginseng: suppression of lung cancer metastasis
- How are universities planning to tackle emissions associated with food and flying?
- Pressure-regulated excitonic feature enhances photocurrent of all-inorganic 2D perovski